Procaps Group SA (PROC)
2.95
+0.37
(+14.34%)
USD |
NASDAQ |
May 17, 16:00
2.95
0.00 (0.00%)
After-Hours: 20:00
Procaps Group Cash from Financing (TTM): -45.56M for Sept. 30, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| September 30, 2023 | -45.56M |
| June 30, 2023 | -21.04M |
| March 31, 2023 | -22.06M |
| December 31, 2022 | -13.63M |
| September 30, 2022 | -59.94M |
| June 30, 2022 | 13.07M |
| Date | Value |
|---|---|
| March 31, 2022 | 44.68M |
| December 31, 2021 | 58.04M |
| September 30, 2021 | 37.53M |
| June 30, 2021 | -25.56M |
| March 31, 2021 | -31.81M |
| December 31, 2020 | -40.51M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-59.94M
Minimum
Sep 2022
58.04M
Maximum
Dec 2021
-8.898M
Average
-21.55M
Median
Cash from Financing (TTM) Benchmarks
| Alvotech | 301.32M |
| Moolec Science SA | 5.974M |
| Perspective Therapeutics Inc | 167.19M |
| Electromed Inc | 0.149M |
| Xtant Medical Holdings Inc | 20.30M |